Precision Medicine in Oncology

When overexpressed in the mice, LRRN4CL led to a higher risk of melanoma spreading to the lungs and correlated with decreased survival.

The sensitivity and specificity of liquid biopsy might be improved through selective venous sampling according to an article in press in The Journal of Vascular and Interventional Radiology.

The results showed that in half of patients with cancers of unknown origin, next-generation sequencing located the primary site of origin and, in those who were matched to a therapy, half achieved a clinical benefit.

A recently published 20-year study suggests that results of the Oncotype DX Genomic Prostate Score are associated with the risk of long-term outcomes in patients with localized prostate cancer.

Research funded by the National Human Genome Research Institute has produced a 22-item guideline for the minimal polygenic risk score-related information that researchers should include in their studies.

An administrator in the Geisinger Cancer Institute discusses the rollout of ClinicalPath.

According to new research, 88% of trials initially matched to patients were eventually classified as false positives when manually screened by a provider.

The FDA has granted full approval to lorlatinib, expanding its indication to include frontline treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC.

ACCC president Randall Oyer, MD, gives insight into the ongoing collaboration between the ACCC and ASCO to foster minority participation in cancer clinical trials.

Excitement around gene therapy is back and greater than before. Although safety remains a concern, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cancer cures will follow.

Tepmetko (tepotinib) was FDA approved for the treatment of adult patients with metastatic non-small cell lung cancer with mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

A report published by the Personalized Medicine Coalition shows that the number of personalized medicines on the market grew at the highest rate ever recorded by the organization from 2016-2020.

During the panel on precision medicine at the Quality Cancer Care Alliance (QCCA) Fall Leadership Summit, the speakers discussed testing every patient upfront with a broad molecular assessment and bringing clinical research to the patient.

A top-5 roundup of some of 2020's advancements in the precision oncology space.

A report published by the Personalized Medicine Coalition (PMC) shows that the number of personalized medicines on the market is growing at the highest rate ever recorded by the organization.

Managing the constantly evolving selection of therapies in oncology can be difficult, but is of the utmost importance to get the right treatment to the right patient, agreed a panel at Patient-Centered Oncology Care® 2020.

A new study validates the application of duplex sequencing in detecting mutations caused by chemical carcinogens.

According to the final panel at Patient-Centered Oncology Care®, clinical pathways can create a new problem: if each payer tries to impose its own pathways, it’s an administrative and ethical nightmare.

The Caris Precision Oncology Alliance has brought together academic institutions and community practices with the goal of performing research and exchanging evidence and ideas for new types of tests, said W. Michael Korn, MD.

The findings help explain why costly CAR T-cell therapy does not work for some patients.

Data presented at the 62nd Annual ASH Meeting demonstrated the clinical utility of Adaptive Biotechnologies’ clonoSEQ next-generation sequencing to detect MRD in multiple myeloma patients.

An oncolytic virus called CF33 developed at City of Hope shows potential for colon cancer treatment and tumor regrowth immunity in mouse models.

Penn Medicine researchers use mice experiments to find a potential solution to the challenge of delivering CAR T cell treatments to solid tumors in glioblastoma.

There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, of University of California, San Francisco, and Caris Life Sciences.

In the past, there was a greater discrepancy in access to precision oncology testing, which has closed somewhat; however, there are some disenfranchised populations who still struggle to access this care.